An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Trial Profile

An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2018

At a glance

  • Drugs APL 2 (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2018 According to an Apellis Pharmaceuticals media release, the company also anticipates presenting additional data in the second half of 2018.
    • 31 Jul 2018 According to an Apellis Pharmaceuticals media release, the company announced data from this trial in June 2018.
    • 19 Mar 2018 According to an Apellis Pharmaceuticals media release, the company remains on track to provide data from this study in first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top